Ultrahypofractionated radiotherapy yields non-inferior 10-year survival outcomes compared to conventional treatment in ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...

China: Researchers have found in a new study that three months of dual antiplatelet therapy in patients treated with Firehawk stents was found to be non-inferior to 12 months of therapy, ...

Eledon Pharmaceuticals (NASDAQ:ELDN) executives discussed recent clinical results and upcoming regulatory plans for its investigational immunosuppressive therapy, referred to in the discussion as ...

Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...

SOL-1 Phase 3 superiority trial results remain masked to dateSOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular ...

In July 2025, 3 4DMT announced its intent to accelerate its 4D-150 4FRONT phase 3 program in wet AMD and lay off approximately 25% of staff. 4DMT noted that this transition supported the company’s ...

USA: A small-volume ophthalmic spray delivering mydriatic medications may offer a child-friendly alternative to traditional eye drops for pupillary dilation, a randomized clinical trial published in ...

Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...

Ocular Therapeutix Inc. OCUL shares are down during Tuesday's premarket session following a significant announcement ...